Psoriasis Clinical Trials in San Francisco

View 19 new treatments for Psoriasis in San Francisco, CA, and other areas near me, such as Antioch, Berkeley, Concord, Daly City, Oakland, Richmond and Vallejo. Every day, Power helps hundreds of psoriasis patients connect with leading medical research.
View 19 trials in San Francisco
Filter (19)

ESK-001 for Psoriasis

Alumis Clinic, Walnut Creek + 2 more

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.Show More

Verified

Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Deucravacitinib for Psoriasis

Bristol-Myers Squibb Clinic, San Francisco + 1 more

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Waitlist
Phase 4
Est. 3 - 6 Weeks
Bristol-Myers Squibb
Study Director

Guselkumab for Scalp Psoriasis

Research Clinic, San Francisco + 1 more

This trial studies how Guselkumab, a medication for psoriasis, affects immune cells in patients with moderate to severe scalp psoriasis. Guselkumab works by blocking a protein to reduce inflammation and symptoms.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Raymond Cho, MD, PhD
Principal Investigator

Deucravacitinib for Psoriasis

Research Clinic, San Francisco + 1 more

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 4 - 6 Weeks
Raymond Cho, MD, PhD
Principal Investigator

Goeckerman Therapy for Psoriasis

Research Clinic, San Francisco + 1 more

This study examines the effect of Goeckerman therapy (a combination of phototherapy and topical crude coal tar), crude coal tar alone, and phototherapy alone on the immunologic and genetic environment within psoriatic skin lesions.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 4 - 6 Weeks
Tina Bhutani, MD
Principal Investigator

Guselkumab for Psoriatic Arthritis

Janssen Clinic, San Leandro + 1 more

This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

Tildrakizumab for Psoriasis

Research Clinic, San Francisco + 1 more

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Raymond Cho, MD, PhD
Principal Investigator

Guselkumab for Psoriasis

Research Clinic, San Francisco + 1 more

This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 3 - 6 Weeks
Wilson Liao, MD
Principal Investigator

Risankizumab for Psoriatic Arthritis

AbbVie Clinic, San Leandro + 1 more

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Waitlist
Phase 3
Est. 6 - 12 Weeks
ABBVIE INC.
Study Director

TAK-279 for Plaque Psoriasis

Takeda Clinic, Fremont + 1 more

This trial is testing a new drug called TAK-279 to see if it can help people with moderate to severe plaque psoriasis. The goal is to find out if TAK-279 can reduce the skin problems better than other available treatments.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Study Director
Study Director
Page 1 of 2

Frequently Asked Questions

How much do psoriasis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do psoriasis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across psoriasis trials in San Francisco, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for psoriasis patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in San Francisco is research being conducted for psoriasis?

Prominent hospitals in San Francisco conducting psoriasis clinical trials include the University of California, San Francisco. As of 2024, there are approximately 5 trials ongoing in the area.

What promising new drugs are being tested?

In San Francisco, psoriasis research is focusing on treatments like Monoclonal Antibodies and Tyrosine Kinase Inhibitors. Notable drugs being studied include Guselkumab, Deucravacitinib, and Etanercept.